Login to Your Account



Topokine Doubles Down on Drug for Double Chins

By Catherine Shaffer
Staff Writer

Wednesday, November 20, 2013
Topokine Therapeutics Inc. has begun dosing in a Phase II trial of its XAF5 gel for reduction of excess submental fat, or double chin. The product is a formulation of XAF5, which reduces cellular lipid content and differentiation in adipocytes.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription